Polaris Partners

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Best Doctors offers an innovative employee health benefit that provides access to global medical expertise for confident healthcare decisions. When facing significant medical choices, members can consult with leading specialists worldwide to ensure accurate diagnoses and appropriate treatments.

Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

CoV Biotechnology is an early-stage biotechnology company dedicated to addressing the challenges posed by the evolving and mutating nature of coronaviruses. The company develops booster vaccines and therapeutics specifically designed to combat variants of the SARS-2 beta coronavirus. By focusing on creating vaccines that offer broad-spectrum protection against both current and future variants, as well as potential zoonotic crossovers from animals to humans, CoV Biotechnology aims to provide effective solutions to enhance immunity and reduce the impact of future coronavirus pandemics.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.

Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.

Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Founded in 2014, Sofregen Medical specializes in developing silk protein-based biomaterials for use in aesthetic procedures and surgeries. The company aims to enhance soft tissue regeneration, restoring function and cosmetic appearance for medical and aesthetic patients worldwide.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Navitor Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases by modulating mTORC1 activity. Founded in 2009, the company is headquartered in Cambridge, Massachusetts.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

KinDex Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery and development of innovative therapeutics aimed at treating metabolic disorders, including diabetes and obesity. Founded in 2009 and headquartered in Seattle, Washington, KinDex focuses on developing molecules that modulate Bitter Taste Receptors (TAS2Rs). These receptors play a significant role in influencing inflammation and metabolic dysfunction across various tissues. One of its primary products, KDT501, is derived from hop extracts and has demonstrated the ability to normalize glucose metabolism and body weight in rodent models. The compound may also improve glucose homeostasis, modify cholesterol and triglyceride levels, and reduce inflammation associated with metabolic disturbances. KinDex's mission encompasses enhancing women's health and addressing chronic diseases through its unique therapeutic approaches.

First Opinion, established in 2013 and headquartered in San Francisco, specializes in a smartphone-based application that connects parents, primarily mothers, with physician mothers for health-related advice and support. This includes guidance on illness, injury, pregnancy, child development, nutrition, lactation, and sleep training. The platform offers 24/7 access to doctors via messaging, with the option to upgrade for treatment services.

Navitor Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases by modulating mTORC1 activity. Founded in 2009, the company is headquartered in Cambridge, Massachusetts.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.

Ascend Health Corporation is a healthcare provider specialising in behavioural health. It operates inpatient and day hospital facilities offering personalised care for children, adolescents, adults, and seniors. Ascend focuses on integrating its services with local community healthcare systems to deliver high-quality mental health and chemical dependency treatments.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Life Line Screening is a prominent provider of community-based preventive health screenings in the United States, focused on raising awareness of unrecognized health issues and promoting follow-up care with personal physicians. The company employs advanced ultrasound technology, similar to that used in hospitals, and screenings are conducted by highly trained healthcare professionals. Results are meticulously reviewed by board-certified physicians to maintain high-quality standards. Life Line Screening offers a range of clinical tests for various health conditions, including heart diseases, diabetes, and cancer, encouraging individuals to take proactive measures regarding their health. The company has established partnerships with several insurance providers, enabling access to its services as covered benefits. A significant clinical study conducted by Oxford University highlighted the importance of early detection, revealing that cardiovascular diseases manifest approximately ten years earlier in men compared to women, thereby underscoring the value of preventive health initiatives.

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

The Center for Health Promotion Inc. delivers tobacco cessation and weight management services to customers nationwide. As an operating unit of Group Health Cooperative (Seattle) for almost 20 years, CHP developed the telephone-based Free & Clear program and established itself a national leader in tobacco cessation. Today CHP continues to deliver tobacco cessation services through health plans, businesses and labor organizations around the country. CHP also provides phone-based tobacco cessation services to residents of Georgia, Maine, Minnesota, Oklahoma, Oregon, Utah, Washington and Wisconsin through contracts with state agencies or coalitions. The company is actively engaged in research trials with major research centers including The Stanford Research Institute in Menlo Park, Calif., the Center for Health Research in Portland, Ore., and the Fred Hutchison Cancer Research Center and Group Health's Center for Health Studies, both in Seattle. This active research is undertaken to help improve CHP's services to smokers and increase scientific understanding of this key health issue.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Founded in 1984, Data Sciences International specializes in biomedical research with a focus on systems physiology and pharmacology. The company provides telemetry devices, instrumentation, software, and services for physiological monitoring, serving various industries including pharmaceuticals, academia, government, and biotechnology. Its product portfolio includes implantable telemetry transmitters, external telemetry devices, signal conditioners, glucose monitoring solutions, infusion pumps, and data services.

Aspect Medical Systems is a pioneering company specializing in brain monitoring technologies that assess the effects of drugs and disease on patient consciousness. The company develops, manufactures, and markets advanced monitoring systems, including BIS monitors and patient sensors, which provide critical information about a patient's level of consciousness during anesthesia and sedation. By enabling clinicians to effectively monitor and manage anesthesia levels in operating rooms, intensive care units, and procedural sedation environments, Aspect Medical Systems enhances the quality of patient care while improving cost-effectiveness. The company's proprietary technologies have established it as a global market leader in the field of consciousness monitoring, ultimately contributing to better clinical outcomes.